BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 12645035)

  • 1. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
    Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
    J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
    Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
    Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT.
    Davis MR; Votaw JR; Bremner JD; Byas-Smith MG; Faber TL; Voll RJ; Hoffman JM; Grafton ST; Kilts CD; Goodman MM
    J Nucl Med; 2003 Jun; 44(6):855-61. PubMed ID: 12791810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
    Nurmi E; Ruottinen HM; Bergman J; Haaparanta M; Solin O; Sonninen P; Rinne JO
    Mov Disord; 2001 Jul; 16(4):608-15. PubMed ID: 11481683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.
    Rinne JO; Bergman J; Ruottinen H; Haaparanta M; Eronen E; Oikonen V; Sonninen P; Solin O
    Synapse; 1999 Feb; 31(2):119-24. PubMed ID: 10024008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M; Ma Y; Barnes A; Dhawan V; Chaly T; Ghilardi MF; Eidelberg D
    Neuroimage; 2004 Apr; 21(4):1497-507. PubMed ID: 15050574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
    Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
    Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.
    Chouker M; Tatsch K; Linke R; Pogarell O; Hahn K; Schwarz J
    Nucl Med Commun; 2001 Jun; 22(6):721-5. PubMed ID: 11403185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
    Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
    Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography/computed tomography dual imaging using 18-fluorine flurodeoxyglucose and 11C-labeled 2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane for the severity assessment of Parkinson disease.
    Li X; Zhang Q; Qin Y; Li Y; Mutaerbieke N; Zhao X; Yibulayin A
    Medicine (Baltimore); 2020 Apr; 99(14):e19662. PubMed ID: 32243399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.